Havasi, A., Pagidipati, N., Bakris, G., Weber, M., Bengus, M., Daga, S., … Granger, C. B. (2024). KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES. In Journal of Hypertension (Vol. 42, pp. e120–e120). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/01.hjh.0001020524.16638.68

Havasi, Andrea, Neha Pagidipati, George Bakris, Michael Weber, Monica Bengus, Shruti Daga, Zhihua Xiang, Tiffany Zee, Ishir Bhan, and Christopher Bull Granger. “KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES.” In Journal of Hypertension, 42:e120–e120. Ovid Technologies (Wolters Kluwer Health), 2024. https://doi.org/10.1097/01.hjh.0001020524.16638.68.

Havasi A, Pagidipati N, Bakris G, Weber M, Bengus M, Daga S, et al. KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES. In: Journal of Hypertension. Ovid Technologies (Wolters Kluwer Health); 2024. p. e120–e120.

Havasi, Andrea, et al. “KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES.” Journal of Hypertension, vol. 42, no. Suppl 1, Ovid Technologies (Wolters Kluwer Health), 2024, pp. e120–e120. Crossref, doi:10.1097/01.hjh.0001020524.16638.68.

Havasi A, Pagidipati N, Bakris G, Weber M, Bengus M, Daga S, Xiang Z, Zee T, Bhan I, Granger CB. KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES. Journal of Hypertension. Ovid Technologies (Wolters Kluwer Health); 2024. p. e120–e120.